Victoza® Receives FDA Approval To Reduce Heart Attack and Stroke in Patients With Type 2 Diabetes and Heart Disease Interview with:

Todd Hobbs, MD Vice President and Chief Medical Officer Novo Nordisk North America

Dr. Hobbs

Todd Hobbs, MD
Vice President and Chief Medical Officer
Novo Nordisk North America Would you tell us a little about liraglutide? How does it work to control diabetes/blood sugar? 

Response: Victoza® (liraglutide) is a human glucagon-like peptide-1 (GLP-1) analog that was approved by the U.S. Food and Drug Administration (FDA) in 2010 to help lower blood sugar in adults with type 2 diabetes. Victoza® is the #1 prescribed (GLP-1) receptor agonist.

Victoza® is a non-insulin, once-a-day medication that helps lower blood sugar levels in adults with type 2 diabetes by increasing glucose-dependent insulin release, inhibiting glucagon secretion, and slowing gastric emptying.

On August 25, the FDA approved a new indication for Victoza®, making it the only type 2 diabetes treatment approved to reduce the risk of major adverse cardiovascular (CV) events, heart attack, stroke and CV death, in adults with type 2 diabetes and established CV disease.

Continue reading

Progressive Incremental Benefits of Targeting Lower HbA1c on Type 2 Diabetes Complications Rates Interview with:

Dr. Samiul Mostafa

Dr. Samiul Mostafa

Dr. Samiul Mostafa
Honorary Clinical Lecturer
Diabetes Trials Unit
University of Oxford What is the background for this study?
Response: In managing people with Type 2 diabetes mellitus (T2DM), international guidelines recommend individualisation of HbA1c (glucose) targets for long term maintenance; however, few data are available on the potential
benefits that different blood sugar control targets might achieve.

Therefore, there is a need to learn more about the incremental benefits
of progressively lowering blood sugar levels.
In this computer modelling study, we used the UKPDS Outcomes Model
version 2.0 to estimate 10-year event rates for myocardial infarction
(MI, heart attack), stroke, blindness and amputation by entering
baseline risk factor variables (for example, weight, height,
LDL-cholesterol, systolic blood pressure) taken from a for a current
population of 5766 people with T2DM. Complication rates were estimated
with HbA1c levels held constant at 10%, 9%, 8%, 7% and 6% for each
individual whilst maintaining their risk factors at their baseline
values. Standard statistical methods were used to calculate relative
risk reductions of complications at each HbA1c level.

Continue reading